Filing Details

Accession Number:
0000947871-24-000498
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-05-20 16:39:38
Reporting Period:
2024-05-15
Accepted Time:
2024-05-20 16:39:38
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1739174 Biomx Inc. PHGE () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1282930 L Carl Gordon C/O Orbimed Israel Gp Ltd.
5 Hahoshlim Street, Building B, 1St Fl.
Herzliya Pituach L3 46686
No No Yes No
1569590 Ltd. Gp Israel Orbimed 5 Hahoshlim Street, Building B, 1St Fl.
Herzliya Pituach L3 46686
No No Yes No
1569821 Partnership Limited Gp Biofund Israel Orbimed 5 Hahoshlim Street, Building B, 1St Fl.
Herzliya Pituach L3 46686
No No Yes No
1706399 Erez Chimovits C/O Orbimed Israel Gp Ltd.
5 Hahoshlim Street, Building B, 1St Fl.
Herzliya Pituach L3 46686
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-05-15 9,280,408 $0.24 13,797,997 No 4 X Indirect See footnotes
Common Stock Disposition 2024-05-15 24,344 $0.38 13,773,653 No 4 S Indirect See footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 X Indirect See footnotes
No 4 S Indirect See footnotes
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Warrants (Right to Buy) Disposition 2024-05-15 9,280,408 $0.00 9,280,408 $0.24
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2023-05-04 2033-05-04 No 4 X Indirect
Footnotes
  1. On May 15, 2024, OrbiMed Israel Partners Limited Partnership ("OIP") exercised pre-funded warrants ("Warrants") to purchase 9,280,408 shares of the Issuer's common stock for $0.244 per share. OIP paid the exercise price on a cashless basis, resulting in the Issuer withholding 24,344 of the Warrant shares to pay the exercise price and issuing to OIP the remaining 9,256,064 shares. The shares of the Issuer's common stock withheld to pay the exercise price of the Warrants are matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), with a portion of OIP's purchase of certain derivative securities on March 15, 2024. OIP will disgorge to the Issuer the statutory "profits" pursuant to Section 16(b) of the Exchange Act that resulted from such transactions.
  2. These securities are held of record by OIP. OrbiMed Israel BioFund GP Limited Partnership ("OrbiMed BioFund") is the general partner of OIP and OrbiMed Israel GP Ltd. ("OrbiMed Israel") is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed Israel and OrbiMed BioFund may be deemed to have voting and investment power over the securities held by OIP and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Israel exercises investment and voting power through an investment committee comprised of Carl L. Gordon and Erez Chimovits.
  3. Each of OrbiMed Israel, OrbiMed BioFund, Carl L. Gordon, and Erez Chimovits disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.